Herpes treatment

ABSTRACT

Various human diseases, including herpes, antibiotic resistant bacterial infections, cutaneous Leishmaniasis, malaria and multiple sclerosis can be treated with injections of garlic juice. The garlic juice is produced by cutting, crushing, or otherwise damaging garlic cloves, and collecting the juice. This garlic juice is dissolved in a carrier solution, such as water or saline, and then injected into the patient.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of, and therefore claims the benefitof and priority to, pending U.S. application Ser. No. 14/329,601, nowU.S. Pat. No. 9,089,597 which in turn claimed priority to and thebenefit of U.S. application Ser. No. 13/739,152, now U.S. Pat. No.8,778,421 filed on Jan. 11, 2013.

FIELD OF THE INVENTION

This invention relates to medical treatment methods and products forvarious afflictions, including herpes and others.

DESCRIPTION OF THE RELATED ART Herpes Simplex Virus

Herpes simplex virus (HSV), Herpesviridae Simplexvirus, is a commonvirus that can cause many unpleasant and recurrent conditions in humans.HSV can enter the host by direct contact and then spread to targettissues. HSV can target the dorsal root ganglia of neurons, and thenremain latent in the targeted tissue. Latent HSV is difficult to target,so a cure of HSV infections is seldom if ever effective, and thevesicles, sores, or lesions can re-appear throughout the infectedindividual's life.

HSV disrupts host cell molecular functions and host cellular structure.HSV can be manifested clinically as host cellular death, resulting inshallow, painful vesicular ectodermal lesions, but other forms ofmanifestation are possible. Target tissues for HSV include the skin ormucous membranes, such as the mouth, skin, vagina, conjunctiva, cornea,etc. The virus typically enters the host cell by direct mucosal contactor by direct contact of abraded skin. Once in the skin, the virusreplicates in epithelial cells and then enters local sensory neurons.The virus travels to the dorsal root ganglia via retrograde axonal flowwhere it establishes permanent residency, and establishes latency.Although latent most of the time, it reactivates intermittently, travelsdown the sensory nerve and causes vesicular eruptions at or near thesite of initial invasion. Alternatively the virus may invade the centralnervous system and cause encephalitis.

A common manifestation of HSV-1 infection is cold sores, especially inor near the mouth or lips. Herpetic conjunctivitis is a somewhat commondisease characterized by swelling and congestion of the palpebralconjunctiva. Keratitis and corneal ulceration may also occur, andherpetic vesicles of the eyelids are typical. Eye lesions typically healrapidly. HSV-1 can also cause herpes labialis, peri-orbital, peri-oral,or peri-nasal skin eruptions and, in older patients, the virus has beenassociated with herpes zoster (“shingles”). Herpes Zoster can causechickenpox in children and shingles in older patients. Herpes zoster isnot HSV-1, but it is a different type of herpes virus.

HSV-2 causes the most prevalent sexually transmitted disease in theUnited States, and visits to physicians for genital herpes infectionscontinue to increase. Many Americans are infected with HSV-2. Theclinical manifestations range from mild genital inflammation to severe,very painful, vesicular lesions and ulceration. Brain damage and deathcan result when HSV-2 is acquired by a newborn infant as it passesthrough an infected birth canal. HSV-2 can also cause cold sores, butthis is less common than for HSV-1.

Garlic

Garlic is a plant that has been used for centuries for medicinal andculinary purposes. It is known that garlic has antimicrobial properties,but the exact components or mechanisms of the antimicrobial propertiesare not certain. Garlic contains many different compounds, includingmany sulfur compounds such as aliin, allicin, ajoene, allyl propyldisulfide, diallyl trisulfide, s-allylcysteine, vinyldithiins,S-allylmercaptocysteine, and others. Besides sulfur compounds, garliccontains amino acids, minerals such as selenium, enzymes such asallinase, peroxidases, and myrosinase, and other compounds. Garliccontains some volatile oils, and many consider these oils to beresponsible for many of garlic's pharmacological properties.

Some attribute the antibacterial activity of garlic to allicin, which isa sulfur compound. Alliin, which is a non-odoriferous derivative of theamino acid cysteine, is separated from the enzyme alliinase while in agarlic clove. However, when the garlic clove is crushed or damaged, thealliinase can come into contact with the alliin to produce the odorous,unstable, water-soluble substance known as allicin (diallylthiosulphinate).

Allicin decomposes readily to form many different intermediate products.The allicin degrades at room temperature, and the rate of degradationincreases with increased temperatures. The degradation products ofallicin are generally not believed to have significant antimicrobialproperties. Therefore, the antimicrobial properties of garlic may beadversely impacted by extended storage or high temperatures. Ajoenes anddithiins are also found in crushed garlic, and have been demonstrated tohave antimicrobial properties.

Many compounds can act together to produce a desired effect, and thevarious antimicrobial properties of garlic may be the result of severalcompounds working in concert. Some of the various compounds may worktogether to combat certain microbes, and various microbes might beinhibited by different compounds or combinations of compounds in garlic.

BRIEF SUMMARY OF THE INVENTION

Herpes infections in human patients can be treated with injections ofgarlic juice. The garlic juice is produced by cuffing, crushing, orotherwise damaging garlic cloves, and collecting the juice. This garlicjuice is dissolved in a carrier solution, such as water or saline, andthen injected into the patient.

BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS

FIG. 1 is a diagram depicting the creation of a garlic solution, and anintravenous (IV) injection of that garlic solution into a patient.

FIG. 2 is a diagram of an IV injection of garlic solution into apatient.

FIG. 3 is a diagram of an intramuscular injection of garlic solutioninto a patient.

DETAILED DESCRIPTION OF THE INVENTION

The use of injections of a garlic solution has been found to aid in thetreatment of many conditions or ailments, as illustrated in FIGS. 1-3.The current inventor has primarily tested and experimented withtreatments for herpes infections, but the inventor has conducted teststhat show injections of garlic solution 14 does have therapeuticbenefits for many other conditions. All testing described herein wasperformed in Iran on volunteer patients who were informed of the risksinvolved, and who freely elected to participate in the inventor'sstudies.

Garlic 10 is a naturally occurring product, and mankind has beenconsuming and using it for many years. Therefore, the chances of adverseside effects from the use of garlic 10 seem remote, especially whencompared to synthetic compounds or other compounds with less history ofuse by man. Mankind's long history with garlic 10, the fact that garlic10 is a natural product, and the fact that garlic 10 has knownantimicrobial properties inspired the inventor to investigate the use ofgarlic 10 to treat herpes and other conditions.

Injection Considerations

Cloves of garlic 10 comprise a multitude of different chemicalcompounds, similar to many other plants and living organisms. It may bepossible to isolate one or a limited selection of chemical compoundspresent in garlic 10 to achieve the same or similar results as describedbelow, and it may even be possible to synthetically produce thecompounds needed. The inventor has discovered useful and beneficialtherapeutic uses for garlic 10 which may derive from a limited number ofchemical compounds within garlic 10, but the specific compounds ofinterest for the uses described have not been identified or isolated forthis disclosure. Therefore, this disclosure describes direct extractionand use of compounds from garlic 10, but it is understood that isolatedcompounds present in garlic 10 may give comparable results. It is alsounderstood that removal of selected compounds from garlic 10 beforeinjection may be beneficial, especially if the patient 30 has knownallergic reactions to specific garlic compounds.

Herpes or other infections can be present at specific, discretelocations within the human body, and the method of treatment needs to beable to reach the pathogens to treat them. When garlic juice 12, or anyother substance, is injected into the bloodstream it rapidly reachesessentially all parts of the body where the herpes virus may be located.Therefore, an injection into the bloodstream can eradicate the herpesvirus wherever it is located, even if the virus is in “hidden” locationssuch as a nerve ganglion, and even when the virus is dormant. The bloodalso circulates by herpes blisters so the garlic components can bedelivered to herpes virus within or near the blisters. The bloodstreamreaches all these locations, so injecting garlic juice 12 provides aneffective means to expose the virus to the garlic components. For thesame reasons, injection of garlic juice 12 can also be effective formany other types of infections, such that the treatment method describedcan be used for conditions other than herpes.

Humans have many natural defenses from the environment at large. Forexample, the skin is a formidable barrier that prevents most compoundsand materials in the environment from entering the body. The stomach andgastrointestinal tract also serve to block many compounds and materialsfrom entering the body. For example, stomach acid may change a compoundbefore it can be absorbed into the blood stream, and thegastrointestinal walls can selectively block certain compounds ormaterials from entering the blood stream. Animals have similar defenses,and this description is also applicable to animals other than humans.

Tests described below have shown that oral or topical application ofgarlic 10 does not provide the same benefits and results as injection ofthe garlic 10. Therefore, it appears some of the beneficial compounds ingarlic 10 are not entering the blood stream through oral or topical use,so the natural defenses of the body must be blocking some compounds outor changing those compounds before they enter the blood stream.

An injection puts all the compounds in the garlic juice 12 directly intothe blood stream, so the natural defenses in the skin andgastrointestinal tract are by-passed. This allows the garlic juice 12 toreach the infection source in the body by way of the blood stream. Theinitial concentration of the garlic compounds is also increased in aninjection, because the entire solution enters the blood stream insteadof selected compounds absorbing over time. Ingestion may expose thecomponents of garlic to enzymes or other compounds, which may speed thedegradation process and may cause the desired compounds to degradebefore entering the blood stream. These are some of the reasons that mayexplain why injecting the garlic juice 12 has better results thaningestion or topical application.

The injection also puts all the compounds in the garlic juice 12 intothe blood stream at the same time, and there could be varying absorptionrates for different compounds through the skin or gastrointestinaltract. Some components in garlic 10 degrade fairly rapidly, and the useof injections serves to rapidly and simultaneously introduce all thecompounds at one time. If more than one compound work together toproduce a desired antimicrobial effect, and one or more of theresponsible compounds degrades over time, then simultaneously adding allthe compounds may improve the effectiveness because the desiredcompounds are present at the same time. Further degradation of thevarious garlic compounds may or may not proceed within the blood. Theblood stream then distributes the components of the garlic juice 12 tothe entire body.

The inventor discovered that injections of high concentrations of garlicjuice 12 were very painful, so it is preferable to dilute the garlicjuice 12 in a solvent of some type. Initial testing with pure garlicjuice 12 or garlic juice 12 diluted with a relatively small amount ofsolvent caused inflammation and soreness at the injection site 28. Forexample, injections of a garlic solution 14 comprising approximately 25%garlic juice 12 and 75% solvent were very painful, so higher dilutionsare preferred. When the garlic juice 12 was diluted and injected moreslowly by IV, the injection pain was significantly reduced, and therewere no notable signs of adverse bodily functions. Most of thesuccessful injections used a solution of no more than 1% garlic juice 12in a solvent, and the solvent used was normal saline. It is preferableto use normal saline 40 or other injection fluids when large quantitiesof liquid are injected, as opposed to injecting large quantities ofwater 44, because the saline 40 or injection fluid more closely matchthe density of blood serum.

The relatively low concentration of garlic juice 12 in the garlicsolution 14 means that a relatively large quantity of liquid should beinjected into the patient to introduce the desired quantity of garlicjuice 12. Intramuscular (IM) injections 20 were performed on someanimals, and the results indicate an IM injection 20 would suffice forintroducing the garlic 10 to the patient 30. However, IM injections 20are not well suited for introducing large quantities of fluid, and IMinjections of garlic solution 14 are very painful, even when usingconcentrations as low as 1%. An intravenous (IV) injection 22 can be setup to gradually introduce fluids into a person over an extended period,such as over several hours, and IV injections of garlic solution 14 aremuch less painful than IM injections, even when using the sameconcentration. The rate of an IV injection 22 can be controlled with aflow controller 24, so the rate of addition can be set as desired.Therefore, most of the experimental tests used IV injection 22. However,initial testing indicates IM injection 20 would also work, but mostlikely with a noticeably higher level of pain.

It is possible to use additives or other compounds to facilitate theinjection. For example, hydrocortisone 32 can be injected prior to, orwith, the garlic solution 14 to help control allergic reactions and tominimize the chances of the patient entering shock. The hydrocortisone32 can be injected at the same location as the garlic solution 14, andeven using the same injection needle 26. The highest bloodconcentrations of hydrocortisone 32, garlic solution 14, or any othercompound are present at the injection site 28, and the injectedcompounds are then diluted and distributed by the blood. Introducing thehydrocortisone through the same hypodermic injection needle 26 as thegarlic juice 12 will minimize the number of injections given to thepatient 30, as well as putting the highest concentration ofhydrocortisone 32 at the point with the highest concentration of garlicsolution 14. However, other injection sites 28 for hydrocortisone 32would likely be effective as well.

The hydrocortisone 32 is preferably injected before the garlic juice 12for a few reasons, but it may be possible to combine the hydrocortisone32 and garlic juice 12 in some embodiments. Injecting the hydrocortisone32 before the garlic juice 12 allows the hydrocortisone 32 to enter theblood to take effect and help prevent shock before the first garlicjuice 12 is injected. It also allows the full quantity of hydrocortisone32 to be in the patient's body before any of the garlic juice 12 isadded, and it also minimizes the chances of a reaction between thehydrocortisone 32 and any of the components of the garlic juice 12. Thehydrocortisone 32 should not be injected more than 24 hours before thegarlic juice 12, so it remains effective. Hydrocortisone 32 injectiontimes of only 1 or 2 minutes before the garlic juice 12 injection wouldmost likely be effective, but essentially any time up to when thehydrocortisone 32 is no longer effective should also work.

An injection of hydrocortisone 32 would normally be expected to inflamea herpetic outbreak, because the hydrocortisone 32 is immunosuppressive.However, the antimicrobial effects of the garlic solution 14 were foundto far outweigh the immunosuppressive effects of the hydrocortisone 32,so there was no noticeable decrease in effectiveness for a garlicsolution injection when hydrocortisone 32 was also used.

Several possible variations for the injection of the garlic solution 14are possible. For example, alcohol could be added to the solvent to helpdissolve oils in the garlic liquid 12, or an antithetic could be addedto reduce pain. Other modifications or changes could also be made.

Garlic Solution Preparation

The preparation of the garlic solution 14 is relatively simple. Normalsaline 40 was selected as the solvent because normal saline 40 is thesimplest solution for IV injections. Normal saline 40 is made by mixingsodium chloride 42, which is common table salt 42, with water 44. Thesalt 42 dissolves in the water 44 to make a solution, and this solutionis typically sterilized before use. Normal saline 40 has a concentrationof about 0.9% sodium chloride 42, but the exact concentration is notcritical. The concentration of salt 42 in normal saline 40 could vary,such as between 0.7% and 1.1%, or between other concentrations, and itis unlikely there would be any significant adverse effect on the patient30. Other solvents could also be used. For example, low quantities ofethanol could be added to the water 44, which may improve thedissolution of some of the oils in the garlic juice 12. There are manyinjection fluids available, and these injection fluids are probablysuitable for use as the solvent. The solvent should be something that isnot toxic, and something that readily dissolves garlic juice 12. Sideeffects of any compounds added to the garlic solution 14 should also beconsidered. The efficacy of the treatment depends on the amount ofgarlic juice 12 injected, and not on the amount of solvent, but theconcentration of the garlic solution 14 does impact the comfort of thetreatment.

The garlic juice 12 was prepared by squeezing and/or cutting the rawcloves of garlic 10. This can be done in a press 50, a juicer, a mortarand pestle, a simple knife, or other techniques. The garlic 10 issqueezed, smashed, cut up, or damaged in some way, and the garlic juice12 is collected. The garlic cloves 10 were sterilized before the garlicjuice 12 was collected, to reduce the chances of infection. Heat canadversely impact the antimicrobial properties of garlic 10, so thegarlic cloves 10 were sterilized chemically instead of thermally. Thiscan be done with hydrogen peroxide or bleach, but other chemicalcompounds could be used. For example, methyl alcohol, ethyl alcohol, isoor n-propyl alcohol, other alcohols, iodine, formaldehyde or otheraldehydes, iodophors, or quaternary ammonium compounds could be used,amongst others.

The garlic 10 should not be excessively heated before use, so heat forsterilization or other purposes should be avoided. Garlic 10 is commonlykept at room temperature, and garlic 10 kept at room temperature waseffective, so there is no need to refrigerate the garlic 10. The garlic10 used in the experiments was fresh, but aged garlic 10 would alsolikely work. The garlic 10 should be raw garlic 10, as opposed to cookedor cured garlic 10, to retain as many natural compounds as possible.Also, the garlic 10 should not be dried, because there will be little orno garlic juice 12 in dried garlic 10, and some of the natural compoundsmay have started to break down or degrade.

Once the garlic juice 12 is extracted from the sterilized garlic cloves10, it is added to the normal saline 40, other injection fluids such asalbumin or dextrose solutions, or some other solvent. The garlic juice12 should be filtered to remove particulates, because particulatesinterfere with injections, and particulates are poorly received in thecirculatory system. The garlic juice 12 can be filtered with standardfilter paper, preferably sterile filter paper, but other filter mediacan be used. The garlic juice 12 can be filtered before being added tothe solvent or after, and it can be filtered more than once. The garlicjuice 12 is dissolved in the solvent by simple mixing, and the result isthe garlic solution 14. The resulting garlic solution 14 should be usedrelatively quickly, because some of the garlic compounds degrade overtime. Garlic solution shelf life would likely increase if stored atlower temperatures. Storage times at room temperature of at least 1 hourafter the garlic juice 12 is extracted from the garlic 10 areacceptable, as verified by the testing.

Based on reported information for garlic 10, it is believed thatallicin, ajoenes, and diallyl disulfide have the most significanteffects on infections, but it also seems likely that more than onedifferent components of garlic act together in a synergistic fashion tocombat infections.

Treatment Procedure

The herpes treatment procedure is relatively simple. The first step isto find a person with herpes who needs treatment, and that personbecomes the patient 30. The treatment is completed by obtaining a garlicsolution 14, and injecting the garlic solution 14 into the patient 30.The effects on the treatment were most visible when the patient hadactive herpes vesicles 34, and the tests were primarily directed towardsboth oral and genital vesicles 34. A herpetic infection is said to beactive when the infected person has sores or vesicles. Testing indicatesthe treatment is effective for both active and inactive herpesinfections, especially the recurrent herpetic whitlow tests describedbelow. Inactive herpes is not visible, so test results are difficult tomeasure. The treatment did stop the active herpes, and speed therecovery, but at least some patients 30 did have subsequent outbreaks ofvesicles 34 which are thought to be due to re-infection, not recurrence,because the human immune system cannot create a complete and permanentimmunity against herpetic infection.

The treatment also appears to cure recurrent herpetic whitlow, where thevesicles 34 were located on the patient's fingers. The cure seems to becomplete, with no recurrent outbreaks. The fingers are not the preferredlocation for the herpes simplex virus, so re-infection after thetreatment is less likely on the fingers.

The method was also found to be effective in treating malaria. Thegarlic juice injections were repeated for 4 days to cover thereproduction cycle of the malaria parasite in the patient 30. The testsubjects were given 1 injection per day for 4 consecutive days, butincreased or decreased frequency may also be possible.

The method was also effective at treating antibiotic resistant bacterialinfections, at least including kidney and urinary tract infections. Thetreatment involved IV injections of garlic solution 14 for 3 consecutivedays, and urethra injections into the bladder and urethra for 2consecutive days. It is expected that other antibiotic resistantbacterial infections could also be effectively treated.

In general, the garlic juice 12 was diluted in normal saline 40 to aconcentration of 1% or less, so at least 100 cubic centimeters (cc) ofnormal saline 40 were used for 1 cc of pure garlic juice 12. The densityof normal saline 40 is slightly greater than 1 gram per cubic centimeter(g/cc), and the density of pure garlic juice 12 is about 1.03 g/cc, sothe garlic solution 14 can comprise about 100 grams of water/saline pergram of garlic juice 12. This concentration is not critical, but it doesappear to provide good results. 0.065 grams (g) of garlic juice 12 wereused for 1 kilogram (kg) of the patient's weight. Therefore, a patientweighing 10 kg would receive a total of 0.65 grams of pure garlic juice12, plus at least about 65 grams of normal saline 40, in a standardinjection. The solvent or saline 40 are used to facilitate the injectionand control pain, but the amount of solvent and the concentration of thegarlic solution 14 does not impact the efficacy of the treatment as longas the total quantity of garlic juice 12 injected remains sufficient.These dosages and ratios applied for almost all the different conditionstested. The amount of garlic juice 12 injected per weight of the patient30 could be varied as well, but the 0.065 g garlic juice 12 per kg ofpatient weight was found to be effective. The quantity described seemedsufficient, because repeated injections were not required for mostconditions, and the patients 30 tolerated the injections well so thequantity does not seem excessive. Also, the inventor noticedproportional treatment effects for smaller quantities of garlic juice12.

Treatment with garlic 10 may also be a valuable veterinary medicine formany ailments of livestock or other animals, including foot and mouthdisease, bronchitis, and others. Garlic 10 is relatively inexpensive andreadily available, which makes its use more economical than some othertreatment options. IV or IM injections of garlic 10 have greatereffectiveness than oral or topical applications for livestock as well.

Results and Testing

Many tests were performed to verify the effectiveness of garlic as atreatment for herpes and other afflictions. All tests were conducted inIran in accordance with local laws.

1. Topical Results, Human Trials

Tables 1 and 2 show the results of topical application of garlic toherpes simplex lesions. These tests were completed in March of 1993. Inthese tests, the human patients were from 20 to 50 years old, and allwere assessed to verify they had no systemic diseases. The patients werebrought in on the first day of manifestation of blisters. The firstpatient to visit was identified as Patient #1, the second patient tovisit was identified as Patient #2, and so on. Odd numbered patientswere treated with garlic, and became the experimental group, and evennumbered patients were not treated at all and were used as a controlgroup.

The experimental group was treated by rubbing cut garlic on herpeticblisters, so the garlic was applied externally or topically. The cutgarlic was applied three times on the first day, and there were nosubsequent treatments. The patients in both the experimental and controlgroup were observed, and the results are shown in Tables 1 and 2, below.

TABLE 1 External use of cut garlic rubbed on the affected area Hoursafter Hours after application Days for Days from application Cessationof for reported crusts to blister mani- for blister to blister growthreduction of fall off festation Patient Age in become after the firstitching and after to crusts # years Gender turbid external use burningtreatment falling off 1 36 M 4 Immediate 1 4 5 3 32 F 5 Immediate 2 4.56.5 5 45 M 4 Immediate 1 5 6 7 27 F 6 Immediate 0.5 3 3.5 9 43 F 5Immediate 1 4 5 11 37 F 5 Immediate 1 4 5 13 34 M 6 Immediate 1 4 5 1525 F 4 Immediate 0.5 3 3.5 17 33 F 6 Immediate 0.5 4 4.5 19 38 M 5Immediate 1 4 5 21 41 F 7 Immediate 0.5 4 4.5 23 21 M 4 Immediate 0.5 33.5 25 24 F 5 Immediate 0.5 4 4.5 27 32 F 7 Immediate 1 3 4 29 20 F 4Immediate 0.5 3 3.5 31 28 M 5 Immediate 1 4 5 33 47 M 7 Immediate 1 4.55.5 35 22 F 5 Immediate 0.5 4 4.5 37 34 F 7 Immediate 0.5 3 3.5 Mean 5.30.82 3.79 4.61

TABLE 2 Control group, no garlic applied to patient Days frommanifestation Days from Patient Age of blisters to manifestation for #(years) Gender cessation of growth crusts to fall off  2 24 F 4 11  4 31F 5 14  6 22 M 4 10  8 43 F 4 11 10 37 M 3 8 12 31 M 4 9 14 38 M 4 11 1647 F 5 13 18 20 F 3 7 20 34 M 4 12 22 27 F 4 11 24 33 F 4 11 26 39 M 514 28 26 F 3 9 30 36 F 3 9 32 21 F 4 10 34 30 M 3 8 36 32 M 4 11 Mean3.8 10.5

Patients in the experimental group reported burning for a few minutesafter application of the garlic, but then they felt better and reportedreduced burning and itching. Within about 5 to 7 hours, the fluid in theblisters for the experimental group changed from clear to a semi-clearor cloudy appearance. In the control group, some blisters would becomecloudy while other blisters in the same area were growing and clear, soit was difficult to specify when the blisters became cloudy. In theexperimental group, all the blisters became cloudy very shortly afterapplication of the garlic, so it was possible to identify when theblisters became cloudy. No growth or extension of the blisters wasobserved in the experimental group after application of the garlic, andthe blisters rapidly started to become wrinkled in appearance, as wellas shrinking and becoming dryer. Therefore, the cessation of growth ofthe blisters, after application of the garlic, was recorded as“immediate.” For the experimental group, the time period frommanifestation of the vesicles (also referred to as blisters) to thefinal crusts falling off was from 3.5 to 6.5 days. However, after aperiod of months, some patients from the experimental group manifestednew blisters, and often in the same site as the blisters that weretreated with garlic.

In the control group, the blisters grew and extended for about 3 to 5days, after which time the patients reported a gradual decline of theburning and itching sensations. After the blisters stopped growing andthe burning and itching sensations declined, the blisters began tobecome wrinkled and dryer in appearance. The total elapsed time frommanifestation of the blisters until the crusts fell off ranged from 7 to14 days, which is notably longer than for the experimental group. Thecontrol group also manifested recurring blisters, which were often inthe site as the previous blisters. Topical treatment with garlic appearsto stop blister growth, but have no impact on recurrent outbreaks.Therefore, it appears that external or topical application of garlic cantreat herpes blisters or outbreaks, but it does not cure the disease oreradicate the herpes virus from the body.

2. Injection Results, Animal Trials

Injections of garlic were examined after the topical applications,because some of the components in the garlic would likely be blockedfrom the blood stream by the gastrointestinal tract, and othercomponents may be changed before entering the blood stream. Initialtests were done on animals.

The first clinical trial was performed on 200 chickens in June of 1993.There were 100 chickens in a control group and 100 chickens in anexperimental group, and all chickens were about 850 grams and 42 daysold. Injections were intramuscular (IM), and each chicken in theexperimental group received 0.6 cubic centimeters (CC) of a 30% garlicsolution. A 30% solution means the solution comprised 30% pure garlicjuice, and 70 percent normal saline. Each chicken in the experimentalgroup was injected with 0.6 cc of the 30% garlic solution three times,where the injections were given two days apart such that all threeinjections were completed over approximately 96 hours. The control groupwas not given any injections.

The experimental and control groups of chickens were kept separate, butin similar coops with similar conditions. A veterinarian controlled thechickens, and they were observed regularly over a two month observationperiod for vital signs, feeding habits, motion, and general observationsby the veterinarian. The veterinarian was of the opinion that theexperimental group was in at least as good health as the control group,and the experimental group even appeared to be somewhat healthier. Themortality rate for the experimental group was 3% less than the controlgroup, and the experimental group had more overall weight gain duringthe observation period.

A random selection of 25 chickens from each of the experimental andcontrol groups were dispatched and evaluated for pathological changes.No pathological differences were noted between the two groups. This testwas repeated a second time, with the only difference being the garlicsolution was injected intravenously (IV) with an insulin syringe intothe vein under the wing. The results were the same as the first test.

Additional tests were performed on other animals, including rabbits,sheep, goats, and cows. Each animal was injected with 0.6 CC of 16.7%garlic solution per kilogram of weight for the animal, so each animalwas injected with a total of 0.1 CC of garlic juice per kilogram ofweight. Garlic juice has a density of approximately 1.03 grams per cubiccentimeter (g/cc). All injected animals were observed for some time, andno mentionable problems were noted. Some injections were done onpregnant animals, and the offspring were then examined. In each case,the offspring was healthy and no health problems, birth defects, lowbirth weights, or other issues or problems were noticed in theoffspring.

Some cows infected with foot and mouth disease were injected with 0.065cc of garlic juice per kilogram of weight, where the garlic juice wasdiluted in 2 liters of normal saline, and all the cows rapidly overcamethe foot and mouth infection. No control group was used with these cowsinfected with foot and mouth disease. In a separate test, 9 sheepinfected with bronchitis were injected with garlic solution. All 9 sheephad lost their wool, were very thin, and one of the sheep was pregnant.Each sheep was injected with 0.065 cc of garlic juice per kilogram ofweight of the animal on 3 separate occasions, with a 2 day intervalbetween the injections. All of the sheep gained weight, grew wool again,and the pregnant sheep gave birth to a healthy, fat lamb.

3. Injection Results, First Human Trials on the Inventor

After reviewing the results from the tests on the animals, the inventordecided to try an IV injection of garlic solution on himself as aninitial human trial. The first trial was performed on Mar. 29, 1996, anda syringe was filled with 25 cc of garlic solution, where the garlicsolution was made from 5 cc of pure garlic juice and 20 cc of normalsaline. The inventor injected 0.5 cc of the garlic solution directlyinto his vein and noticed a very biting and sharp pain that started atthe injection point and followed the path of the vein to the inventor'sheart. The inventor waited several minutes, and then mixed the remaining24.5 cc of garlic solution into 500 cc of normal saline, and thencontinued injecting the diluted garlic solution over the course of 2hours.

The inventor monitored his vital signs during the injection of garlicsolution, including his blood pressure, breathing, heart rate, andtemperature. The inventor also tested his complete blood count (CBC),serum glutamic oxaloacetic transaminase (SGOT), and serum glutamicpyruvate transaminase (SGPT) tests both before the injection, and 16hours after the injection. The inventor noted his heart beat increasedto 110 to 115 beats per minute after the initial (high concentration)injection, and this condition continued for approximately 4 hours afterfinishing all the injections. The inventor's SGOT test before theinjection was within the normal range of 0-37, and 16 hours after theinjection the SGOT test increased to 43. The inventor's SGPT test beforethe injection was within the normal range of 0-41, and 16 hours afterthe test the SGPT was 57. The inventor repeated these tests 3 days afterthe injection, and all the results were within the normal ranges andwere almost the same as before the injection. The inventor's weight wasapproximately 70 kilograms (kg) for the entire test period describedherein.

Nine hours after the injection, the inventor felt pain beginning at thepoint where the injection was made along the vein in the inventor'sforearm, and the skin was red and inflamed for about 25 centimeters (cm)on this route. Four days after the injection, the inventor's arm was nolonger sore, red, or inflamed, and these conditions did not re-appear.The inventor also had a mild headache and mild nausea after theinjection, but the headache stopped 2 days after the injection and thenausea stopped about 6 hours after the injection. For 4 days after theinjection, the inventor noticed reduced pains along the route of theinjection vein when waking in the morning as compared to when he went tobed the previous night.

Before the injection, the inventor had acute herpetic gingivostomatitison the left side of his hard palate, with soreness. The inventor noticedthe associated burning and pain were gone within 6 hours of theinjection, and 2 days after the injection the inventor was asymptomatic.The inventor experienced vertigo, with unknown etiology, for severalyears before the injection. The inventor had noticed his vertigo waspresent in both the standing and laying positions and the vertigo becameworse when he caught a cold. When the inventor shook his head thevertigo became worse and he became nauseated. The inventor noticed agradual decline in his vertigo over the 3 months after the injection,and the vertigo was completely absent 3 months after the injection. Theinventor did a second injection 2 months after the first, as summarizedbelow.

The inventor completed several IV injections into himself after thefirst one, as summarized below. In these tests, the garlic solution wasinjected over a 5 hour period, the garlic was more dilute than theinitial 0.5 cc injection, and there was no phlebitis (redness orsoreness of the injection vein), and no sign of any allergic reaction orshock.

Inventor Self-Injection Schedule. cc garlic juice/ Date cc normal salineComments 29 Mar. 1996 5/520 Started at 5/20 garlic to normal saline 29May 1996 4/500 25 Mar. 1997 5/500 26 Mar. 1997 4.5/500   27 Mar. 19974.5/500   28 Mar. 1997 4.5/500    7 Sep. 1997 4/500 11 Sep. 1997 5/50026 Dec. 1997 4/500 15 Jun. 1998 5/500

After the 10 self-injections, the inventor determined there were nonotable or irreversible side effects when injection 5 cc of pure garlicjuice diluted in 500 cc of normal saline into a 70 kg person. At thispoint, the inventor decided to extend the research to willing andproperly informed volunteers. The inventor initiated human trials of IVinjection of garlic solution with willing volunteers (who reviewed andsigned approvals to participate) on the 24^(th) of March, 1999, andtests continued for approximately 2 years.

4. Injection Results, Human Trials on Volunteers.

The volunteers were individuals who experienced recurrent outbreaks ormanifestations of blisters on or around the mouth from the herpes virus.All volunteers were 20 to 50 years old, all volunteers were assessed toverify they had no systemic diseases, and it was determined that allvolunteers would come in for initiation of the process on the first dayof manifestation of blisters.

The volunteers were randomly divided into three groups: Group A; GroupB; and Group C, and the testing was not blind because the volunteerscould identify which individuals received the garlic solution. A totalof 4 volunteer patients had genital herpes. Two of these patients wererandomly assigned to Group A (patients 22 and 37,) one of these patientswas randomly assigned to Group B (patient 29), and the last of thesepatients was randomly assigned to Group C. The patient with genitalherpes who was placed in the control Group C dropped out of the programand that patient's results are not reported below. Each group received adifferent treatment, and the treatment started when they came in on thefirst day of blister manifestation. Group A received 100 milligrams (mg)of hydrocortisone by IV one hour before IV injection of the garlicsolution. Group B received IV injection of the garlic solution, but nohydrocortisone. Group C received no treatment. The first volunteer whocame in with blisters was placed in Group A and first received IVhydrocortisone and IV garlic solution one hour later. The secondvolunteer who came in with active blisters was placed in Group B andreceived an IV garlic solution injection. The third patient who came inwith active blisters was placed in Group C and received no treatment,and this sequential group assignment process was repeated for all thevolunteers.

The garlic solution for all IV injections was prepared by mixing 0.065cc of pure garlic juice for each kilogram of weight of the patient in500 cc of normal saline. Therefore, the concentration of the garlicsolution would vary somewhat depending on the weight of the patient. Forall the patients the following data was observed and recorded: (1)duration of growth of the vesicles from the first manifestation tostopping their growth, which is when the blisters began to show dryingand appear wrinkled; (2) duration of time from the beginning of theburning and itching sensation to the end of the burning and itchingsensation, as reported by the volunteers, and this period matched theduration of the growth from the first manifestation to stopping thegrowth, so it is not separately reported here; and (3) duration of timefrom the injection to the time when the final crusts would fall off.

In all cases, the growth of the blisters stopped when the garlicsolution was injected. The testing was conducted over a period of 2years, and a total of 82 volunteer patients were seen. Patients wereallowed to drop out of the program, and they would be replaced when theydropped out. When the test was completed, there were 28 volunteerpatients in Group A, 29 volunteer patients in Group B, and 25 volunteerpatients in Group C. Patients were observed at the testing facility for48 hours after an injection. The patients were also cared for during the48 hour observation period.

There were no notable differences in the results for Groups A and B,except that some of the Group B patients did have a stronger adversereaction to the injection, such as more severe nausea or vomiting. Someof these patients had vesicles or blisters of the genital organs, andsome patients had oral blisters. All patients in Groups A and B reportedthe end of burning, itching, and tingling in the blisters within about 6hours. The blisters of all patients in Groups A and B stopped growing atthe time of the garlic solution injection, and drying and wrinkling ofthe vesicles was clearly visible within 20 to 24 hours after theinjection. The crusts from the blisters fell off after 4-5 days from thetime of the injection for all patients in Groups A and B. Those patientswith genital blisters were cured with essentially identical healingtimes as for the oral blisters. No differences in treatment or efficacywere seen between the oral or genital blisters.

In the control Group C, the blisters grew with burning, itching, andtingling for 3 to 5 days, and then gradually stopped. The crusts fromthe blisters fell off after 6 to 13 days in control Group C. After thecompletion of the test, the volunteer patients in Group C were allowedto receive IV injections of the garlic solution with hydrocortisone (asfor Group A), and the patients who elected to do this are referred to asGroup D. All subsequent testing used hydrocortisone as a precaution forprevention of any allergic reactions. The results for the Group Dpatients can be compared against the same individual when thatindividual received no treatment as a member of control Group C. Thepatient numbers were retained when patients moved from Group C to GroupD, so the identity of individuals who served as both an experimentaltest subject and a control test subject can be determined by referringto the patient number. The results for Group D were consistent with theresults for Groups A and B.

The members of Groups A, B, and D have reduced blister recurrencefrequency compared to before the treatment. Also, recurrences are indifferent locations than before or during the treatment. It appears therecurrences after treatment with garlic solution injection are not thesame infection that was treated, but rather a new re-infection. Thefollowing tables document the test results discussed above.

TABLE 3 Group A. These volunteers received 100 mg hydrocortisone by IVfollowed by 0.065 cc pure garlic juice per kg of patient weight,dissolved in 500 cc of normal saline, by IV. Days from Days from blisterDays from blister cc garlic manifestation injection to manifestationPatient Weight juice to end of crusts falling to crusts # Age Gender(kg) injected growth off falling off 1 32 M 75 4.8 1 3.5 4.5 4 27 M 674.4 1.5 4 5.5 7 43 M 83 5.3 1 4 5 10 39 M 79 5.0 1 4 5 13 37 F 65 4.2 14 5 16 45 M 80 5.2 1 5 6 19 25 F 64 4.0 1 4 5 22 33 M 73 4.7 2 4.5 6.525 31 M 69 4.5 1 4 5 28 31 M 78 5.0 1 4 5 31 42 F 84 5.4 1 4 5 34 35 M77 5.0 1 5 6 37 21 F 63 4.0 1.5 4.5 6 40 38 M 82 5.3 1 4 5 43 29 M 694.5 1 4.5 5.5 46 41 M 70 4.5 1 4 5 49 30 F 67 4.3 1 4 5 52 44 M 78 5.0 14 5 55 37 F 71 4.5 1.5 4 5.5 58 42 M 67 4.3 1 4 5 61 29 F 65 4.2 1 3.54.5 64 36 F 76 4.9 1 4.5 5.5 67 45 M 81 5.2 1.5 4 5.5 70 41 M 77 5.0 1 45 73 34 M 73 4.7 1 4.5 5.5 76 26 M 69 4.4 1.5 4 5.5 79 32 F 67 4.3 1 4 582 34 M 78 5.0 1 4 5 Mean 4.13 5.25

TABLE 4 Group B. These volunteers received 0.065 cc pure garlic juiceper kg of patient weight, dissolved in 500 cc of normal saline, by IV.Days from blister Days from Days from cc garlic manifestation injectionto blister Patient Weight juice to end of crusts falling manifestationto # Age Gender (kg) injected growth off crusts falling off 2 47 M 805.2 1 4 5 5 34 M 75 4.8 1 4 5 8 29 M 67 4.3 1 3 4 11 37 F 78 5.0 1 4.55.5 14 22 F 66 4.2 1.5 4 5.5 17 45 M 73 4.7 1 4 5 20 37 M 83 5.3 1 4 523 31 F 68 4.4 1 4 5 26 34 M 81 5.2 1.5 4.5 6 29 25 F 65 4.2 1 3 4 32 43M 84 5.4 1 5 6 35 35 M 70 4.5 1 4 5 38 33 M 79 5.1 1 4 5 41 38 F 72 4.61 4.5 5.5 44 49 F 68 4.4 1 4 5 47 37 M 82 5.3 1 4 5 50 28 M 75 4.8 1 3 453 40 F 73 4.7 1 4.5 5.5 56 32 M 73 4.7 1 4 5 59 33 M 70 4.5 1 4 5 62 26M 74 4.8 1 3.5 4.5 65 39 M 85 5.5 1 4 5 68 42 M 77 5.0 1 4 5 71 36 F 724.6 1.5 4 5.5 74 44 M 92 5.9 1 4.5 5.5 77 23 M 67 4.3 1 3.5 4.5 80 32 F71 4.6 1 4 5 83 30 M 80 5.2 1 3 4 86 27 M 66 4.2 1 4 5 Mean 3.95 5.00

TABLE 5 Group C. These volunteers received no injection of garlic juice,and served as the control group. Days from blister Days from blisterPatient Weight manifestation to manifestation # Age Gender (kg) end ofgrowth* to crusts falling off 3 35 F 71 5 11 6 37 M 82 3 8 9 48 M 75 613 12 29 M 69 4 10 15 36 F 69 3 8 18 27 M 67 2 6 21 42 M 78 5 12 24 45 M76 3 9 27 43 F 75 4 11 30 37 M 79 3 10 33 23 F 58 4 10 36 32 F 66 4 1139 40 F 74 5 13 42 31 M 68 3 8 45 47 M 91 4 11 48 35 M 76 2 6 51 37 F 715 12 54 44 M 85 3 8 57 25 M 73 2 6 60 28 F 62 3 9 63 42 M 80 2 8 66 32 F78 3 10 69 33 M 76 3 10 72 40 M 72 4 11 75 28 M 74 3 9 Mean 3.52 9.6*Determining when the growth of a blister stops is not very accurate forthe control group, because some parts of the blister would stop growingwhile other parts continued to grow. The measure is accurate for theexperimental groups because all growth stopped upon injection of thegarlic solution.

TABLE 6 Group D. These volunteers received 0.065 cc pure garlic juiceper kg of patient weight, dissolved in 500 cc of normal saline, by IV.The volunteers in this group were from the control Group C, and thistesting was performed subsequent to the testing with Groups A, B, and C.Results for individuals with outbreaks both with and without thetreatment can be seen by referring to the patient numbers, becausepatient numbers were retained between Groups C and D. Days from Daysfrom Days from blister injection to blister cc garlic manifestationcrusts manifestation Patient Weight juice to end of falling to crusts #Age Gender (kg) injected growth off falling off 6 37 M 82 5.3 1 3 4 9 48M 75 4.8 1 5 6 12 29 M 69 4.5 1 4 5 15 36 F 69 4.5 1 3.5 4.5 21 42 M 785.0 1 4.5 5. 27 43 F 75 4.8 1 4 5 30 37 M 79 5.1 1 4 5 33 23 F 58 3.7 14 5 42 31 M 68 4.4 1 3.5 4.5 45 47 M 91 5.9 1 4 5 48 35 M 76 4.9 1 4 551 37 F 71 4.6 1 4.5 5.5 57 25 M 73 4.7 1 3 4 60 28 F 62 4.0 1 4 5 63 42M 80 5.2 1 3.5 4.5 69 33 M 76 4.9 1.5 4 5.5 75 28 M 74 4.8 1 4 5 Mean3.91 4.91

TABLE 7 Portions of Group C. These results are extracted from Table 5for the volunteers who participated in Groups C and D, for directcomparison purposes. Days from blister Days from blister Patient Weightmanifestation to manifestation to # Age Gender (kg) end of growth*crusts falling off  6 37 M 82 3 8  9 48 M 75 6 13 12 29 M 69 4 10 15 36F 69 3 8 21 42 M 78 5 12 27 43 F 75 4 11 30 37 M 79 3 10 33 23 F 58 4 1042 31 M 68 3 8 45 47 M 91 4 11 48 35 M 76 2 6 51 37 F 71 5 12 57 25 M 732 6 60 28 F 62 3 9 63 42 M 80 2 8 69 33 M 76 3 10 75 28 M 74 3 9 Mean3.47 9.475. Injection Results, Human Intentional Infection and Cure.

The inventor analyzed the test results, and decided to conduct an invivo treatment test on tissue with a visible herpes infection. Therecurrent herpetic whitlow infection recurs frequently and often theskin does not completely heal after an active blister. The recurrentherpetic whitlow infections can have lengthy outbreaks, which gives timeto monitor the results. The fact that recurrent herpetic whitlowfrequently recurs for lengthy periods, and the skin does not completelyheal after an outbreak, makes recurrent herpetic whitlow a goodcondition to determine if the garlic juice injections simply treat anactive outbreak, or completely cure the herpes infection. Recurrentherpetic whitlow is also less common that oral or genital herpes, andthe fingers are not a preferred site for herpes infections sore-infection after the treatment is less likely. The inventor conductedthis test by intentionally infecting himself with the herpes virus,verifying the infection was present and recurrent, and curing theinfection with injections of garlic solution.

To begin the test, the inventor decided to infect his left thumb withthe herpes virus. The inventor cleaned the medial side of his left thumband active vesicles of a patient's lip with soap and warm water, andthen rinsed them with sterile normal saline. The inventor then cut someblisters on the patient's lip with a sterile scalpel, and then used thesame scalpel with remaining residue from the blisters to make someshallow oblique cuts to the subcutaneous layer of the inventor's leftthumb on the medial side. These cuts on the inventor's thumb were thencovered be sterile wet gauze and latex for 24 hours.

The inventor noticed an itching and tingling feeling at the location ofthe cuts after about 10 days, and then a deep vesicle appeared that wasextending to the surface of the skin. This vesicle was torn byscratching. In the following weeks more vesicles appeared, withassociated itching and tingling sensations. A dermatologist confirmedthe inventor had herpetic whitlow on his thumb using the Tzanck test.The inventor waited for 2 months and verified the herpetic whitlowinfection was recurrent, or recurrent herpetic whitlow.

After verifying the infection was recurrent, the inventor initiated thetreatment by orally taking 1.5 cc of pure garlic juice 3 times a day for10 days. This did not stop the blister growth, and the infectionremained recurrent. The inventor then applied cryotherapy with ice 3times a day, for 15 minutes per application, for 3 consecutive days.This caused the blisters to subside, but the infected area neverreturned to a normal and healthy state, and the blisters recurred later.The inventor then applied garlic topically to the blisters 3 times a dayfor 3 consecutive days. This caused the blisters to subside, but theyrecurred later.

The inventor then simultaneously orally administered 1.5 cc of puregarlic juice 3 times a day for 10 days, and during the first 3 days theinventor also applied cryotherapy and topical garlic applications to theblisters, as described above. The blisters subsided, but recurred againwith inflammation of the skin. When inactive, the external layer of skinappeared thin, wrinkled, and sometimes exfoliated. This area of theinventor's thumb was approximately the same size as a bean, or about 8millimeters (mm) by 15 mm, and it had a frosted white appearance indepth but it did not protrude or bulge out. The oral and topical effortsat treatment described above were conducted over a 9 month period, andthe recurrent herpetic whitlow remained recurrent, or kept coming back.The inventor confirmed the recurrent infection was herpetic whitlow withthe Tzanck test.

The inventor then decided to investigate injections of garlic solutionas a treatment method. On 3 May 2006, the inventor intravenouslyinjected himself with 5 cc of pure garlic juice dissolved in 500 cc ofnormal saline. Beginning on 4 May 2006, the inventor noticed a reductionof the tingling and itching, and after 6 weeks there were no visiblesigns of recurrent herpetic whitlow on the inventor's thumb, and thislocation returned to a normal shape and appearance, as with a healthythumb. There was no scar, no exfoliation, pain, itching, or tingling,and there has been no recurrence of the recurrent herpetic whitlow onthe inventor's thumb at least through 4 Jan. 2013.

The inventor then found six volunteer patients with recurrent herpeticwhitlow who agreed to take the garlic solution injections (on thecondition the inventor would verify the safety by simultaneously takingthe garlic solution injection himself, which the inventor agreed to do).These six volunteers were patients of dermatologists, and Tzanck testingverified all had herpetic whitlow, and there was no indication of anysecondary infections. Five other patients who were verified to haverecurrent herpetic whitlow agreed to participate in a control group.

These 6 volunteer patients with recurrent herpetic whitlow received IVinjections of 0.065 cc pure garlic juice per kg of patient weight in 500cc normal saline on 18 Nov. 2006 Inflammation and swelling for all 6patients gradually reduced, and was no longer visible after 4 days. All6 patients reported the pain, burning, tingling, and itching sensationdecreased beginning the day after the injection. No new vesiclesappeared on any of the 6 patients, and the existing vesicles that werevisible on the surface of the skin were eliminated in the first week.Existing vesicles from below the surface of the skin rose and exfoliatedgradually over a period of 3 to 4 weeks, and after 6 to 8 weeks therewas no sign of recurrent herpetic whitlow. After the 8 week period, all6 patients reported no further signs of recurrent herpetic whitlow andno recurrence of the infection through at least 1 Nov. 2012.

The five patients who agreed to participate in the control groupcontinue to have signs of recurrent herpetic whitlow with periodicoutbreaks. Based on these results, the inventor has concluded thatrecurrent herpetic whitlow can be treated and cured by IV injection ofgarlic juice, and even by a single IV injection of garlic juice.

6. Human Test Results for Other Conditions.

Three patients infected with malaria volunteered to receive injectionsof garlic solution to determine the results. The malaria infections wereverified by consultation with the patient's physician. These threepatients received IV injections of 0.065 cc of pure garlic juice perkilogram of weight of the patient, where the garlic juice was dissolvedin at least 500 cc of normal saline, and sometimes more saline. The IVinjections were administered once per day for four consecutive days,where the injections were at approximately the same time of day. Thethree patients left the care of the inventor after 6 days, but thepatient's physician verified there was no sign or symptom of malaria forat least 6 months after the injections. The inventor used 4 injectionsspread over 4 days to cover the life cycle of the malaria parasite inthe body.

Two patients with multiple sclerosis (MS) volunteered and received oneIV injection of 0.065 cc of pure garlic juice per kilogram of weight ofthe patient, where the garlic juice was dissolved in 500 cc of normalsaline. The MS condition was verified by a neurologist treating thepatients. These patients were followed for 6 months, and they reportedfeeling better and having improved motion after the injection. Thegarlic solution was given to the MS patients based on the theory that MSmay be caused by HSV-6.

Three patients living in the Iranian city of Esfahan volunteered fortreatment of their cutaneus leishmaniasis condition. Cutaneusleishmaniasis is a skin infection caused by single celled parasites thatproduces large boils or sores. These three patients were treated on thefirst day with an IV injection of 0.065 cc of pure garlic juice perkilogram of weight of the patient, where the garlic juice was dissolvedin 500 cc of normal saline. The boils were also treated topically withraw garlic 3 times a day, beginning on the same day as the injection andcontinuing for a total of 5 consecutive days. The sores healed rapidly,with no prolonged effects.

Some vaginal infections were cured by topical application of garlic byshooting 20% garlic solution into the vaginal cavity. Preliminarylaboratory tests were performed on the infectious agents to determinewhich patients were amenable to treatment with garlic.

Two patients with grand mal epilepsy were given one IV injection ofgarlic solution per day for two consecutive days. The IV injection was0.065 cc of pure garlic juice per kilogram of weight of the patient,where the garlic juice was dissolved in 500 cc of normal saline. Thepatients stated that they felt better after the injection, and thenumber and intensity of epileptic seizures was reduced.

Three volunteer male patients with kidney and urinary tract infectionswere found, where the infections were resistant to antibioticmedications. These infections were bacterial, and they were one exampleof an antibiotic resistant bacterial infection. These patients received0.065 g garlic juice per kg of patient weight, diluted in normal saline,by IV injection. These patients also received 5 cc of 10% garlicsolution in normal saline injected into the urethra such that 4 cc wereinjected into the bladder and 1 cc was injected into the urethra. On the1^(st) and 2^(nd) day, both the IV and urethra injections wereadministered. On the 3^(rd) day, only the IV injection was administered.The patients were completely cured in about 4-5 days after the 1^(st)garlic juice injections, as verified by urinary analysis.

Other conditions that have shown promise, based on experimental use andobservation and reports from human patients, include:

a) The treatment of cystits in women by injection of 0.5 cc of a 10%solution of pure garlic juice in normal saline into the urinary duct.The patients reported relief of pain and discomfort within 15 minutes ofthe injection.

b) Many dysenteries were successfully treated orally.

c) Various skin infections, including acne, were successfully treated bytopical application and/or IV injection. Dilute garlic solutions werenot as effective as pure garlic juice for topical treatment of acne.

d) After drainage of an abscess, a 10% garlic solution was injected intothe abscess space and there was no extension of that abscess.

e) IV injections of garlic solutions, as described above, have reducedthe healing period for the common cold and influenza.

f) Dilute solutions of garlic juice were used for burns for maintenanceand prevention of infections.

g) Many patients have stated relief from a wide variety of afflictionsafter an injection of a garlic solution. The cause of these afflictionswas never determined, but the afflictions that were reported as improvedinclude chronic fatigue, mild depression, mild amnesia, nightmares, andvertigo.

The inventor believes the use of garlic juice is an initial step in thetreatment of a wide variety of infections, and can open the door to animproved state of health care. While the invention has been describedwith respect to a limited number of embodiments, those skilled in theart, having benefit of this disclosure, will appreciate that otherembodiments can be devised which do not depart from the scope of theinvention as disclosed here. Accordingly, the scope of the inventionshould be limited only by the attached claims.

What is claimed is:
 1. A method for treating foot-and-mouth disease inan animal comprising: (a) identifying an animal with suffering fromfoot-and-mouth disease; (b) obtaining a garlic solution comprisinggarlic juice and water; and (c) injecting the garlic solution into theanimal.
 2. The method of claim 1 where the quantity of garlic juiceinjected into the animal is at least 0.065 grams per kilogram of weightof the animal.
 3. The method of claim 1 where the garlic solution isinjected into the animal intravenously.
 4. The method of claim 1 whereinthe garlic solution is injected into the animal via intramuscularinjection.
 5. The method of claim 1 further comprising injecting ahydrocortisone solution into the animal.
 6. The method of claim 5wherein where the hydrocortisone solution is injected prior to thegarlic solution injection.
 7. The method of claim 5 wherein where thehydrocortisone solution is injected at the same site as the garlicsolution injection.
 8. The method of claim 5 wherein the animal is acow.
 9. The method of claim 1 wherein the garlic juice is extracted fromraw garlic cloves, and where the raw garlic cloves are sterilized beforethe garlic juice is extracted.
 10. The method of claim 9 wherein thegarlic cloves are sterilized via chemical sterilization.
 11. The methodof claim 1 wherein the animal is a cow.
 12. The method of claim 1wherein the garlic solution further comprises an additive.
 13. Themethod of claim 12 wherein the additive is ethanol.
 14. The method ofclaim 13 wherein the animal is a cow.
 15. A method for treatingfoot-and-mouth disease in a cow comprising: (a) identifying a cow withsuffering from foot-and-mouth disease; (b) obtaining a garlic solutioncomprising garlic juice and water; and (c) injecting the garlic solutioninto the cow.
 16. The method of claim 15 where the quantity of garlicjuice injected into the animal is at least 0.065 grams per kilogram ofweight of the animal.
 17. The method of claim 16 wherein the garlicjuice is extracted from raw garlic cloves, and where the raw garliccloves are sterilized before the garlic juice is extracted.